Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2005-05-17
2005-05-17
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S009340, C424S009400, C424S133100, C424S153100, C424S155100, C424S178100, C424S181100, C424S183100, C530S387300
Reexamination Certificate
active
06893625
ABSTRACT:
A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.
REFERENCES:
patent: 4468464 (1984-08-01), Cohen et al.
patent: 4486538 (1984-12-01), Bogoch
patent: 4650756 (1987-03-01), Old et al.
patent: 4708862 (1987-11-01), Baldwin
patent: 4724212 (1988-02-01), Epstein
patent: 4724213 (1988-02-01), Epstein
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 5091178 (1992-02-01), Hellstrom et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5500302 (1996-03-01), Phillips et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5545403 (1996-08-01), Page
patent: 5545404 (1996-08-01), Page
patent: 5545405 (1996-08-01), Page
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 0 120 694 (1984-10-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 184 187 (1986-06-01), None
patent: WO 8303971 (1983-11-01), None
patent: WO 8601533 (1986-03-01), None
patent: WO 8702671 (1987-05-01), None
patent: WO 8702776 (1987-05-01), None
patent: WO 8803145 (1988-05-01), None
Roitt, “Essential Immunology”, Blackwell Scientific, Publications, Oxford, UK, pp. 242-243, 1984.*
Bodmer, M.W., “Recombinant Antibodies for Clinical Use,”Abstracts of Oral Presentations, p. 526 (1986).
Boulianne, G.L. et al., “Production of Functional Chimaeric Mouse/Human Antibody,”Nature 312:643-646 (Dec. 1984).
Brown, B.A. et al., “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Research 47:3577-3583 (Jul. 1987).
Brüggemann, M. et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies,”J. Exp. Med. 166:1351-1361 (Nov. 1987).
Cabilly, S. et al., “Generation of Antibody Activity from Immunoglobulin Polypeptide Chains Produced inEscherichia coli,”Proc. Natl. Acad. Sci. USA 81:3273-3277 (Jun. 1984).
Clark, E.A. et al., “Role of the Bp35 Cell Surface Polypeptide in Human B-cell Activation,”Proc. Natl. Acad. Sci. USA 82:1776-1770 (Mar. 1985).
Clark, E.A. et al., Abstract 0147—“Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy,”Journal of Cellular Biochemistry(Supplement 9A), p. 63 (Jan./Feb. 1985).
Gillies, S.D. et al., “Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody,”Hybridoma 10(3):347-356 (Jan. 1991).
Hellstrom et al. in Baldwin et al., “Monoclonal Antibodies for Cancer Detection and Therapy,”Academic Press, New York, pp. 34-36 (1985).
International Search Report for PCT Publication No. 88/03145 (Feb. 1988).
Jones, P.T. et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,”Nature 321:522-525 (May/Jun. 1986).
Liu, A.Y. et al., “Chimeric Mouse-Human IgGl Antibody that can Mediate Lysis of Cancer Cells,”Proc. Natl. Acad. Sci., USA 84:3439-3443 (May 1987).
Liu, A.Y. et al., “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity,”J. Immunol. 139:3521-3526 (Nov. 1987).
Marx, J.L., “Antibodies Made to Order,”Science 229:455-456 (Aug. 1985).
Morrison, S.L. et al., “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constrant Region Domains,”Proc. Natl. Acad. Sci., USA 81:6851-6855 (Nov. 1984).
Morrison, S.L. et al., “Transfectomas Provide Novel Chimeric Antibodies,”Science 229:1202-1207 (Sep. 1985).
Mujoo, K. et al., “A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2,”Cancer Immunology Immunotherapy 34:198-204 (1991).
Nadler, L.M. et al., “A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin,”J. Clin. Invest. 67:134-140 (Jan. 1981).
Neuberger, M.S., “Making Novel Antibodies by Expressing Transfected Immunoglobulin Genes,”TIBS, 347-349 (Sep. 1985).
Neuberger, M.S., “A Hapten-Specific Chimaeric IgE Antibody with Human Physiological Effector Function,”Nature 314:268-270 (Mar. 1985).
Neuberger, M.S., “Recombinant Antibodies Possessing Novel Effector Functions,”Nature 312:604-608 (Dec. 1984).
Nishimura Y. et al., “Recombinant Human-House Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen,”Canc. Res. 47:999-1005 (Feb. 1987).
Nose, M. et al., “Biological Significance of Carbohydrate Chains on Monoclonal Antibodies,”Proc. Natl. Acad. Sci., USA 80:6632-6636 (Nov. 1983).
Oi, V.T. et al., “Chimeric Antibodies,”BioTechniques 4:214-221 (May/Jun. 1986).
Press, O. et al., Abstract 864—“Serotherapy of Malignant B Cell Lymphomas with Monoclonal Antibody IF5 (ANTI-CD20),”Twenty-Second Annual Meeting of the American Society of Clinical Oncology5:221 (Mar. 1986).
Robinson, R.R. et al., “Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities,”Hum. Antibod. Hybridomas 2:84-93 (Apr. 1991).
Roit, I.M., “Essential Immunology,”Blackwell Scientific Publications, Oxford, U.K., p. 165 (1984).
Sahagan, B.G. et al., “A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen,”J. Immunol. 137:1066-1074 (Aug. 1986).
Stashenko, P. et al., “Characterization of a Human B Lymphocyte-Specific Antigen,”J. Immunol. 125:1678-1685 (Oct. 1980).
Steplewski, Z. et al., “Biological Activity of Human-Mouse IgG1, IgG2, IgG3, and IgG4 Chimeric Monoclonal Antibodies with Antitumor Specificity,”Proc. Natl. Acad. Sci., USA85:4852-4856 (Jul. 1988).
Sun, L.K. et al., “Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A,”Proc. Natl. Acad. Sci., USA 84:214-218 (Jan. 1987).
Sun, L.K. et al., “Chimeric Antibodies with 17-1A Derived Variable and Human Constant Regions,”Hyridoma5 Supp. 1:17-20 (Apr. 1986).
Takeda, S. et al., “Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences,”Nature314: 452-454 (Apr. 1985).
Tan, L.K. et al., “A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells,”J. Immunol. 135:3564-3567 (Nov. 1985).
Walker, C. et al., “Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation,”Eur. J. Immunol. 17(6):873-880 (Jun., 1987).
Williams, G.T. et al., “Production of Antibody-Tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow,”Gene 43:319-324 (1986).
Wood, C.R. et al., “The Synthesis and In Vivo Assembly of Functional Antibodies in Yeast,”Nature 314:446-449 (Apr. 1985).
IDEC Pharmaceuticals Corp. and Genentech, Inc., Product Sheet for Rituxan®(1998).
Munro, “Uses of chimeric antibodies,”Nature, 312:597 (Dec. 13, 1984).
Dickson, “Scientist Produce Chimeric Monoclonal Abs.,”Genetic Engineering News, 5(3), p. 1 and p. 33 (Mar. 1985).
Alexander, A. et al., “γ heavy chain disease in man: cDNA sequence supports partial gene deletion model,”Proc. Nat. Acad.
Ledbetter Jeffrey A.
Liu Alvin Y.
Robinson Randy R.
Royalty Pharma Finance Trust
Saunders David
Testa Hurwitz & Thibeault LLP
LandOfFree
Chimeric antibody with specificity to human B cell surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antibody with specificity to human B cell surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antibody with specificity to human B cell surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3416383